Physician profile
Ryan M Lustig
NPI 1124246335
$4,206.11
in general payments reported to CMS, 2019-2025
34 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $266 · 2021: $641 · 2022: $213 · 2023: $540 · 2024: $736 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,617.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $338.34 | 2021-2025 | Nxstage System One |
| Mallinckrodt Hospital Products INC. | $312.07 | 2020-2025 | Terlivaz, Acthar |
| Vifor Pharma, INC. | $260.63 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $259.44 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $256.51 | 2023-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $254.89 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $254.38 | 2023-2025 | Ozempic, Rivfloza, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $229.87 | 2023-2025 | |
| Akebia Therapeutics INC | $219.87 | 2019-2023 | Auryxia |
| Astrazeneca Pharmaceuticals Lp | $214.75 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $164.96 | 2020-2025 | Krystexxa, Tavneos |
| Medtronic, INC. | $156.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $139.64 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $134.27 | 2023-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $99.67 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $99.31 | 2019-2025 | Jynarque |
| Daiichi Sankyo INC. | $98.69 | 2019-2021 | |
| Amicus Therapeutics, INC. | $96.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.31 | 2024-2025 | Livtencity |
| Apellis Pharmaceuticals, INC. | $63.95 | 2025 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.73 | 2024-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $54.71 | 2019 | |
| Chiesi USA, INC. | $48.98 | 2025 | Elfabrio |
| Ardelyx, INC. | $42.33 | 2025 | Ibsrela |
| Bard Peripheral Vascular, INC. | $40.46 | 2019 | |
| Glaxosmithkline, LLC. | $40.24 | 2020-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $35.97 | 2019-2024 | Liberty Select Cycler, Nxstage System One |
| Invivyd INC | $34.13 | 2025 | Pemgarda |
| Alexion Pharmaceuticals, INC. | $30.45 | 2022-2024 | Ultomiris |
| Horizon Therapeutics Plc | $25.68 | 2021 | |
| Pharmacosmos Therapeutics INC. | $24.22 | 2024 | Monoferric |
| Vantive US Healthcare LLC | $23.67 | 2025 | Renal - Pd |
| Recor Medical INC | $14.47 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ultragenyx Pharmaceutical INC. | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lustig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.